Citigroup’s Arcturus Therapeutics ARCT Stock Holding History
Bought
Maintained
Sold
Other funds holding ARCT
Citigroup's ARCT Position: Q3 2026 in Review
Citigroup reduced its Arcturus Therapeutics (ARCT) stake by 5.1% in Q3 2026, selling an estimated $6.94K and leaving 12,363 shares worth $169K. The position accounts for ﹤0.01% of the portfolio, ranked #4283.
Citigroup first reported a position in ARCT in Q1 2014 and has held it in 46 quarters since. The position peaked at $4.86M in Q2 2021. 114 funds tracked by Wall St. Rank hold ARCT as of Q3 2026.
- Citigroup held 12,363 shares of Arcturus Therapeutics worth $169K as of Q3 2026.
- Citigroup sold 664 Arcturus Therapeutics shares in Q3 2026, an estimated $6.94K.
- Arcturus Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #4283 holding.
- Citigroup first reported a position in Arcturus Therapeutics in Q1 2014 and has held it in 46 quarters since.
- Citigroup's Arcturus Therapeutics position peaked at $4.86M in Q2 2021.
- 114 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2026.
Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.